

## PERFORMANCE DATA SHEET

1819

For maximal recovery of contents  
please quick spin vial before opening

# Human CD268(BAFFR)-muIg Fusion Protein\*

CATALOG#: 524-020

QUANTITY: 25 µg

CONCENTRATION: 0.5 mg/ml

**Molecular Structure:** A soluble molecule consisting of the extracellular (60aa) domain of human BAFFR fused to the murine IgG2a Fc (232 aa). Predicted monomeric weight: 33.5 kd.

**Transfectant Cell Line:** CHO

**INFORMATION:** The human B cell activating factor (BAFF) and APRIL(a proliferation inducing ligand) are both type II molecules belonging to the TNF superfamily. They are expressed by non-B cells, and are down regulated by mitogenic stimulation(2). BAFF and APRIL bind to at least two receptors: TACI (transmembrane activator and CAML-interactor) and BCMA (B cell maturation antigen), both of which are restricted to B cells(3,4). Ligation of these receptors with recombinant BAFF dramatically increases IgM production by peripheral blood B cells(1). A third receptor for BAFF (BAFF-R) has been described(5). BAFF and BAFFR knockout mice have a reduced numbers of mature B cells in the periphery, however TACI and BCMA knockouts do not share this phenotype, suggesting that BAFF-R may be the primary receptor for BAFF in mice(8,9,10). Cell surface BAFF can be proteolytically cleaved to form a soluble trimeric molecule(2). Levels of soluble BAFF correspond with levels of autoantibodies in Sjogren's Syndrome(11). Recombinant human BAFFR-muIg binds to recombinant BAFF-muCD8 and can inhibit binding of this molecule to receptors on Raji cells.

**References:** 1) Schneider P., J. Tschopp, et al. *J. Exp. Med.* 1999, 189(11):1747-1756. 2) Shu, H.B., H. Johnson, W.H. Hui. *J Leukoc Biol* 1999, 65:680-683. 3) Marsters, S.A., A. Ashkenazi, et al. 2000, *Curr Biol* 10:785-788. 4) Xia, X., H. Hsu, et al. 2000, *J Exp Med*, 192(1): 137-143. 5) Thompson J.S., C. Ambrose, et al. *Science* 2001, 293: 2108-2111. 6) Roschke, V, T.S. Migone, et al. *J Immunol.* 2002, 169: 4314-4321. 7) MacLennan, C.M., C.G. Vinuesa, 2002, *Immunity* 17:235-238. 8) B. Schiemann, et al, (2001) *Science* 293: 2111-2114. 9) S.M. Harless, et al, (2001) *Curr Biol* 11: 1988-1989. 10) *Mol Cell Biol* (2001) 21: 4067-4074. 11) X. Mariette, et al, (2003) *Ann Rheum Dis* 62: 168-171.

**STORAGE CONDITIONS:** Store at 2 - 5°C. Freeze/Thawing is not recommended.

**PRODUCT STABILITY:** Product should retain activity for at least 12 months after shipping date when stored as recommended. Ship Date: \_\_\_\_\_

**BUFFER:** 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5mg/ml Gentamicin Sulfate (as a preservative).

**PRODUCTION:** Human BAFFR-muIg fusion protein was purified from (low FBS containing) tissue culture supernatant of CHO transfectants using size exclusion and Protein A chromatography.

**PERFORMANCE:** Five x 10<sup>5</sup> human **Raji** cells were washed and incubated 45 minutes on ice with 80 µl of **BAFF-muCD8 (cat# 525-020)** at 5 µg/ml. Cells were washed twice and incubated with 2<sup>o</sup> anti-muCD8α/PE Catalog #260-050), after which they were washed three times, fixed and analyzed by FACS. Cells stained positive with a mean shift of 1.62 log<sub>10</sub> fluorescent units when compared to a buffer control. **This binding was 91% inhibited when reagent was pre incubated with 100 µg/ml BAFFR-muIg**

*\*This Product is intended for Laboratory Research use only.*